Bortezomib (brand name Velcade) is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma, usually in combination with other therapies. Given by subcutaneous or intravenous injection, it works by blocking protein breakdown in cancer cells, causing them to die. Common side effects include peripheral neuropathy, fatigue, gastrointestinal issues, and low blood cell counts.
See It Styled On Instagram
- No access token
Reviews
There are no reviews yet.